To include your compound in the COVID-19 Resource Center, submit it here.

Second Genome's NASH candidate well tolerated in Phase I

Second Genome Inc. (South San Francisco, Calif.) said non-alcoholic steatohepatitis (NASH) candidate SGM-1019

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE